vs
GDEV Inc.（GDEV）与IOVANCE BIOTHERAPEUTICS, INC.（IOVA）财务数据对比。点击上方公司名可切换其他公司
GDEV Inc.的季度营收约是IOVANCE BIOTHERAPEUTICS, INC.的1.4倍（$119.9M vs $86.8M），IOVANCE BIOTHERAPEUTICS, INC.同比增速更快（17.7% vs 13.3%）
GDEV Inc.是一家游戏娱乐控股公司，在纳斯达克上市，总部位于塞浦路斯利马索尔。该公司前身为2014年成立的游戏公司Nexters，2023年6月改组为控股集团，是欧洲前五的独立移动游戏企业，旗下拥有Nexters Studio、Cubic Games、Royal Ark、Game Gears、Light Hour Games等工作室，分支机构分布在塞浦路斯、亚美尼亚、哈萨克斯坦等地。
艾欧万斯生物治疗公司是一家总部位于加利福尼亚州圣卡洛斯的生物制药初创企业，专注于开发针对癌症的肿瘤浸润淋巴细胞（TIL）疗法，致力于为癌症患者提供创新型的免疫治疗方案。
GDEV vs IOVA — 直观对比
营收规模更大
GDEV
是对方的1.4倍
$86.8M
营收增速更快
IOVA
高出4.4%
13.3%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $119.9M | $86.8M |
| 净利润 | $16.6M | — |
| 毛利率 | — | 67.4% |
| 营业利润率 | 15.5% | -84.7% |
| 净利率 | 13.9% | — |
| 营收同比 | 13.3% | 17.7% |
| 净利润同比 | 13.0% | — |
| 每股收益（稀释后） | $0.90 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GDEVIOVA
| Q4 25 | — | $86.8M | ||
| Q3 25 | — | $67.5M | ||
| Q2 25 | $119.9M | $60.0M | ||
| Q1 25 | — | $49.3M | ||
| Q4 24 | — | $73.7M | ||
| Q3 24 | — | $58.6M | ||
| Q2 24 | $105.8M | $31.1M | ||
| Q1 24 | — | $715.0K |
净利润GDEVIOVA
| Q4 25 | — | — | ||
| Q3 25 | — | $-91.3M | ||
| Q2 25 | $16.6M | $-111.7M | ||
| Q1 25 | — | $-116.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-83.5M | ||
| Q2 24 | $14.7M | $-97.1M | ||
| Q1 24 | — | $-113.0M |
毛利率GDEVIOVA
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
营业利润率GDEVIOVA
| Q4 25 | — | -84.7% | ||
| Q3 25 | — | -140.7% | ||
| Q2 25 | 15.5% | -189.8% | ||
| Q1 25 | — | -245.8% | ||
| Q4 24 | — | -117.5% | ||
| Q3 24 | — | -152.1% | ||
| Q2 24 | 14.4% | -327.6% | ||
| Q1 24 | — | -16464.6% |
净利率GDEVIOVA
| Q4 25 | — | — | ||
| Q3 25 | — | -135.3% | ||
| Q2 25 | 13.9% | -186.2% | ||
| Q1 25 | — | -235.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -142.7% | ||
| Q2 24 | 13.9% | -312.2% | ||
| Q1 24 | — | -15800.8% |
每股收益（稀释后）GDEVIOVA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0.90 | $-0.33 | ||
| Q1 25 | — | $-0.36 | ||
| Q4 24 | — | $-0.24 | ||
| Q3 24 | — | $-0.28 | ||
| Q2 24 | $0.81 | $-0.34 | ||
| Q1 24 | — | $-0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.6M | $297.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-129.4M | $698.6M |
| 总资产 | $210.2M | $913.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GDEVIOVA
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | $41.6M | $301.2M | ||
| Q1 25 | — | $359.7M | ||
| Q4 24 | — | $323.8M | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | $50.8M | $412.5M | ||
| Q1 24 | — | $356.2M |
股东权益GDEVIOVA
| Q4 25 | — | $698.6M | ||
| Q3 25 | — | $702.3M | ||
| Q2 25 | $-129.4M | $698.5M | ||
| Q1 25 | — | $767.9M | ||
| Q4 24 | — | $710.4M | ||
| Q3 24 | — | $773.5M | ||
| Q2 24 | $-118.7M | $768.5M | ||
| Q1 24 | — | $680.0M |
总资产GDEVIOVA
| Q4 25 | — | $913.2M | ||
| Q3 25 | — | $904.9M | ||
| Q2 25 | $210.2M | $907.4M | ||
| Q1 25 | — | $966.7M | ||
| Q4 24 | — | $910.4M | ||
| Q3 24 | — | $991.1M | ||
| Q2 24 | $282.8M | $964.3M | ||
| Q1 24 | — | $869.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.6M |
| 自由现金流经营现金流 - 资本支出 | — | $-61.9M |
| 自由现金流率自由现金流/营收 | — | -71.3% |
| 资本支出强度资本支出/营收 | — | 10.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-336.2M |
8季度趋势，按日历期对齐
经营现金流GDEVIOVA
| Q4 25 | — | $-52.6M | ||
| Q3 25 | — | $-78.7M | ||
| Q2 25 | — | $-67.4M | ||
| Q1 25 | — | $-103.7M | ||
| Q4 24 | — | $-73.3M | ||
| Q3 24 | — | $-59.0M | ||
| Q2 24 | — | $-98.4M | ||
| Q1 24 | — | $-122.3M |
自由现金流GDEVIOVA
| Q4 25 | — | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | — | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | — | $-98.9M | ||
| Q1 24 | — | $-126.5M |
自由现金流率GDEVIOVA
| Q4 25 | — | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | — | -317.9% | ||
| Q1 24 | — | -17685.3% |
资本支出强度GDEVIOVA
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 583.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GDEV
暂无分部数据
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
